Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

LYMPHOMA

Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era

Leukemia volume 36, pages 1416–1420 (2022)Cite this article

Subjects

The introduction of anti-CD20 antibodies has improved the population-level survival of patients with follicular lymphoma (FL) [1, 2]. Nevertheless, specific subgroups still carry a poor prognosis even in modern times [3, 4], and the optimal therapeutic approach to high-risk patients remains debatable [5].

Given the heterogeneity in outcomes, treatment decision-making in FL may, amongst other things, be guided by population-based estimates on the leading causes of death (COD). These estimates are also relevant for risk communication since they help quantify the real-world cumulative incidence of lymphoma-related death and death due to competing causes. Furthermore, temporal changes in COD provide insight into the effect of treatment advances on FL prognosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Cumulative incidences of lymphoma-related death, death due to other malignancies, and death due to other causes with 95% confidence intervals of patients with follicular lymphoma according to age groups, disease stages, and periods of diagnosis.

References

  1. Dinnessen MAW, van der Poel MWM, Tonino SH, Visser O, Blijlevens NMA, de Jong D, et al. Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989-2016. Leukemia. 2021;35:1683–95.

    Article  CAS  Google Scholar 

  2. Junlen HR, Peterson S, Kimby E, Lockmer S, Linden O, Nilsson-Ehle H, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. Leukemia. 2015;29:668–76.

    Article  CAS  Google Scholar 

  3. Dinnessen M, Visser O, Tonino S, Poel M, Blijlevens N, Kersten M, et al. The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: a population‐based study. eJHaem. 2020;1:489–97.

    Article  Google Scholar 

  4. Dinnessen MAW, Visser O, Tonino SH, Posthuma EFM, Blijlevens NMA, Kersten MJ, et al. Conditional relative survival among patients with follicular lymphoma: a population-based study in the Netherlands. Blood Cancer J. 2021;11:12.

    Article  Google Scholar 

  5. Becnel MR, Nastoupil LJ. Follicular lymphoma: past, present, and future. Curr Treat options Oncol. 2018;19:32.

    Article  Google Scholar 

  6. Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA, Jager JJ. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol. 1993;22:369–76.

    Article  CAS  Google Scholar 

  7. Harteloh P. The implementation of an automated coding system for cause-of-death statistics. Inf Health Soc Care. 2020;45:1–14.

    Article  Google Scholar 

  8. Harteloh P, de Bruin K, Kardaun J. The reliability of cause-of-death coding in The Netherlands. Eur J Epidemiol. 2010;25:531–8.

    Article  Google Scholar 

  9. Hinchliffe SR, Lambert PC. Flexible parametric modelling of cause-specific hazards to estimate cumulative incidence functions. BMC Med Res Methodol. 2013;13:13.

    Article  Google Scholar 

  10. Hinchliffe SR, Lambert PC. Extending the flexible parametric survival model for competing risks. Stata J. 2013;13:344–55.

    Article  Google Scholar 

  11. Sarkozy C, Maurer MJ, Link BK, Ghesquieres H, Nicolas E, Thompson CA, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol: Off J Am Soc Clin Oncol. 2019;37:144–52.

    Article  CAS  Google Scholar 

  12. Hester LL, Park SI, Wood WA, Stürmer T, Brookhart MA, Lund JL. Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes. Cancer. 2019;125:1101–12.

    Article  Google Scholar 

  13. Karim S, Xu Y, Quan ML, Dort JC, Bouchard-Fortier A, Cheung WY. Generalizability of common cancer clinical trial eligibility criteria in the real world. J Clin Oncol. 2018;36:e18616. e

    Article  Google Scholar 

  14. Latouche A, Allignol A, Beyersmann J, Labopin M, Fine JP. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol. 2013;66:648–53.

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank the registration clerks of the Netherlands Cancer Registry (NCR) for their dedicated data collection. The nationwide population-based NCR is maintained and hosted by the Netherlands Comprehensive Cancer Organisation (IKNL). The results presented in this paper are based on calculations by IKNL using non-public microdata from Statistics Netherlands. Under certain conditions, these microdata are accessible for statistical and scientific research. For further information: microdata@cbs.nl.

Author information

Authors and Affiliations

  1. Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands

    Manette A. W. Dinnessen, Carolien C. H. M. Maas & Avinash G. Dinmohamed

  2. Amsterdam UMC, University of Amsterdam, Department of Hematology, Cancer Center Amsterdam, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands

    Manette A. W. Dinnessen, Sanne H. Tonino, Marie José Kersten & Avinash G. Dinmohamed

  3. Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands

    Carolien C. H. M. Maas & Avinash G. Dinmohamed

  4. Department of Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands

    Otto Visser

  5. Department of Internal Medical, Reinier de Graaf Gasthuis, Delft, The Netherlands

    Eduardus F. M. Posthuma

  6. Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands

    Eduardus F. M. Posthuma

  7. Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands

    Nicole M. A. Blijlevens

  8. Department of Hematology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands

    Pieternella J. Lugtenburg

  9. Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, The Netherlands

    Avinash G. Dinmohamed

Authors
  1. Manette A. W. Dinnessen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carolien C. H. M. Maas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sanne H. Tonino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Otto Visser
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eduardus F. M. Posthuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicole M. A. Blijlevens
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marie José Kersten
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Pieternella J. Lugtenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Avinash G. Dinmohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AGD designed the study; MAWD analyzed the data; OV collected the data; MAWD wrote the manuscript with contributions from all authors, who also interpreted the data, and read, commented on, and approved the final version of the manuscript.

Corresponding author

Correspondence to Manette A. W. Dinnessen.

Ethics declarations

Competing interests

MJK: research support from Kite/Gilead and honoraria and/or travel support from Kite/Gilead, Novartis, Miltenyi Biotech, Roche, BMS/Celgene. SHT: honoraria from Incyte, Takeda, Celgene and travel support form Roche/ Gilead. PJL: research funding from Takeda, Servier, Roche and honoraria for advisory boards from Takeda, Servier, Roche, Genmab, Incyte, Regeneron, Celgene. The other authors have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dinnessen, M.A.W., Maas, C.C.H.M., Tonino, S.H. et al. Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era. Leukemia 36, 1416–1420 (2022). https://doi.org/10.1038/s41375-022-01535-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-022-01535-y

Search

Advanced search

Quick links